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Background: The AID/APOBECs are deaminases that act on cytosines in a diverse set of pathways and some of
them have been linked to the onset of genetic alterations in cancer. Among them, APOBEC1 is the only family
member to physiologically target RNA, as the catalytic subunit in the Apolipoprotein B mRNA editing complex.
APOBEC1 has been linked to cancer development in mice but its oncogenic mechanisms are not yet well
understood.
Results: We analyze whether expression of APOBEC1 induces a mutator phenotype in vertebrate cells, likely
through direct targeting of genomic DNA. We show its ability to increase the inactivation of a stably inserted
reporter gene in a chicken cell line that lacks any other AID/APOBEC proteins, and to increase the number of
imatinib-resistant clones in a human cellular model for chronic myeloid leukemia through induction of mutations
in the BCR-ABL1 fusion gene. Moreover, we find the presence of an AID/APOBEC mutational signature in esophageal
adenocarcinomas, a type of tumor where APOBEC1 is expressed, that mimics the one preferred by APOBEC1 in vitro.
Conclusions: Our findings suggest that the ability of APOBEC1 to trigger genetic alterations represents a major layer in
its oncogenic potential. Such APOBEC1-induced mutator phenotypes could play a role in the onset of esophageal
adenocarcinomas. APOBEC1 could be involved in cancer promotion at the very early stages of carcinogenesis, as it is
highly expressed in Barrett's esophagus, a condition often associated with esophageal adenocarcinoma.Background
APOBEC1 (Apolipoprotein B mRNA editing enzyme,
catalytic polypeptide 1) is part of the RNA editing com-
plex that physiologically deaminates C6666 to U in the
transcript of human Apolipoprotein B, a major compo-
nent in lipid transport [1-3]. APOBEC1 exerts this func-
tion in the small intestine in humans, and in the liver in
rodents.
APOBEC1 was the first identified member of the AID/
APOBEC protein family, a group of cytosine deaminases
that target nucleic acids in a diverse set of pathways to
induce C > U changes [4,5]. Most of these proteins are
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unless otherwise stated.essential for all secondary antibody diversification pro-
cesses [6,7], and the APOBEC3s act in a defense path-
way against retroviruses and mobile elements [8,9].
The only well-characterized target for APOBEC1 is
the mRNA for Apolipoprotein B; however, additional
target mRNAs have been identified [10-12], and it has
been also suggested that APOBEC1 regulates mRNA sta-
bility through its ability to bind RNA [13,14]. On the
other hand, APOBEC1 can also target DNA in bacteria
and in vitro [15-17]. Based on this activity, other roles
have been suggested, from controlling DNA methylation
[18,19], to being part of a restriction pathway against
retroviruses and mobile elements, similar to the APO-
BEC3s [20-25].
APOBEC1 expression has been linked to cancer: trans-
genic mice and rabbits constitutively expressing APO-
BEC1 in the liver develop hepatocellular carcinoma [26],l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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reduces the number of polyps and tumors in the gastro-
intestinal tract [27]. The oncogenic potential of APO-
BEC1 has been attributed mostly to its ability to target
RNA [3]. However, we hypothesize that the oncogenic
role of APOBEC1 is related to its ability to target DNA.
This hypothesis is corroborated by the evidence that aber-
rant activity of other AID/APOBECs underlies the onset of
genetic alterations in human cancer [28-35].
In direct support of this notion, here we show in two
cellular models that expression of APOBEC1 induces a
mutator phenotype. In addition, we show the presence
of the mutational signature of the AID/APOBECs in
human esophageal adenocarcinomas, a type of tumor in
which APOBEC1 is highly expressed.
Results and discussion
Rat APOBEC1 induces a mutator phenotype in a chicken
cell line
In order to investigate the ability of rat APOBEC1 - the
best characterized among the mammalian homologues -
to induce a mutator phenotype, we used DT40 cells, a
chicken lymphoma B cell line that has been extensively
employed to study the mutational activity of AID [36],
the only catalytically active member of the AID/APO-
BEC family present in the chicken genome [17,37]. A
derivative DT40 clone in which AID has been knocked
out (sIgM+ ψV− AID−/−) [38] has enabled us to assay the
effects of APOBEC1 in the absence of other DNA muta-
tors. We first inserted a single-copy enhanced green
fluorescent protein (EGFP) reporter gene in the DT40
genome, so that inactivation of the EGFP could be easily
detected through fluorescence-activated cell sorting (FACS)
analysis, in a similar way to that used to study AID-
dependent mutations [36]. We then transfected independ-
ent DT40GFP clones with constructs expressing either rat
APOBEC1 or a control plasmid, and we followed the ex-
pression of the EGFP reporter gene in clones selected to
stably express APOBEC1 (Figure S1A in Additional file 1).
Starting from 2 weeks after transfection we observed the
rise of a distinct EGFP(−) population in the clones express-
ing APOBEC1 (Figure 1A,B). At 4 weeks after transfection,
the median percentage of the EGFP(−) cells in the
APOBEC1-expressing clones was four times larger than in
the control clones. Indeed, sorted EGFP(−) cells remained
negative after expansion. It seemed unlikely that this find-
ing could result from an effect of APOBEC1 on RNA, since
this would likely alter the overall level of EGFP RNA rather
than abolish its expression in individual cells. To confirm
this we sorted the GFP(−) population from APOBEC1- and
control-transfected cells and sequenced the EGFP coding
region to detect the presence of mutations. Approximately
a quarter of the sequences bore mutations. The mutation
pattern observed in the samples expressing APOBEC1 wasdifferent from the mutational background in the controls
(Figure 1C): C/G base pairs were preferentially mutated in
the APOBEC1 samples, and the changes were mainly trans-
versions, a pattern reminiscent of the one observed after
AID-dependent deamination in DT40 cells [38].
Each member of the AID/APOBEC family preferen-
tially targets cytosines within a specific sequence con-
text: this preference can be quite strict (for example,
CCC for APOBEC3G, TC for APOBEC3B) or more re-
laxed (for example, WRC for AID, YC for APOBEC1).
Indeed, the sequence context of the mutations at cyto-
sine residues observed in the EGFP reflects that ob-
served in vitro and in bacteria for APOBEC1 [15,16,39],
especially with regard to the preference for a thymine
directly upstream to the mutated C and the avoidance of
adenines (Figure 1D; Additional file 2).
Human APOBEC1 is able to mutate DNA in bacteria
Human APOBEC1 - in contrast to other mammalian ho-
mologues - exerts only a minor effect on retroviruses
and mobile elements [20,22,24,40]. This has cast doubts
on its ability to target DNA. We therefore cloned human
APOBEC1 in a bacterial expression vector and used this
in the rifampicin-resistance reversion assay, a test widely
used to study AID/APOBEC-mediated induction of a
mutator phenotype. The outcome of the experiments
reveals that human APOBEC1 is effective as a DNA muta-
tor (Figure 2A). Sequence analysis of the rpoB gene from
rifampicin-resistant clones shows that the mutations in-
duced by human APOBEC1 closely resemble those induced
by the rat homologue (Figure 2B).
APOBEC1 induces a mutator phenotype in human K562 cells
Having confirmed that both rat and human APOBEC1
could effectively target DNA, we tested whether the
APOBEC1-induced mutator phenotype could affect
drug-resistance dynamics in a cancer cellular model.
To this end, we used human K562 cells, a model for
chronic myeloid leukemia (CML) bearing a BCR-ABL1
chromosomal translocation. The BCR-ABL1 fusion gene
provides support for the cellular growth, and treatment
with imatinib, a tyrosine kinase inhibitor, results in cell
death due to blockade of the BCR-ABL1 kinase domain.
Mutations in BCR-ABL1 can produce imatinib-resistant
clones: it has been shown that exogenous overexpression of
AID induces mutations that can confer resistance to the
drug by disrupting the interaction of BCR-ABL1 with the
drug [41,42]. AID/APOBECs do not seem to be expressed
in these cells, either treated or not with imatinib. After
obtaining stably transfected clones, we cultured K562 cells
expressing APOBEC1, AID as a positive control, or a con-
trol plasmid (Figure S1B in Additional file 1) in the pres-
ence of imatinib to select clones resistant to the drug. In
line with our expectations, a higher number of colonies was
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Figure 1 APOBEC1 induces mutations in DT40 cells. (A) The inactivation of the EGFP transgene in DT40 cells was assayed by monitoring the size
of a distinct EGFP(−) population in transfectants expressing either APOBEC1 or a control plasmid (Figure S1A in Additional file 1). Flow cytometric analysis
of representative DT40GFP clones stably transfected with APOBEC1 or with the control plasmid. The red boxed area indicates the EGFP(−) population
considered for the analysis. (B) Plot depicting the inactivation of the EGFP in independent transfectants, with the median for each construct indicated.
The measurements were taken at the indicated times (P< 0.05 for each time-point). The sorted EGFP(−) cells did not regain fluorescence after expansion.
(C) Mutation pattern obtained after sequence analysis of independent EGFP fragments from sorted EGFP(−) APOBEC1- and vector-transfected
DT40 cells. The number of sequences analyzed and the total number of bases is indicated in parentheses (P = 0.012 by Fisher’s exact test). Only
non-clonal mutations were considered, which is likely to underestimate the number of mutations in the case of preferred mutational hotspots.
(D) Local sequence context for the cytosine residues present on both strands of the analyzed GFP fragments (expected) and for the mutated
cytosines (observed) in the APOBEC1-expressing clones.
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BEC1, both rat or human, compared with controls,
with APOBEC1-expressing clones outnumbering those
expressing AID (Figure 3). After confirming that the se-
lected clones were able to grow in imatinib-supplemented
medium, we amplified the region of the BCR-ABL1 gene
encoding the imatinib binding site to evaluate the presence
of mutations. Sequence analysis of individual clones
confirmed the presence of mutations in the ABL1 tyro-
sine kinase domain, mostly located at residues near thecatalytic pocket (Table 1). Taking into account the
number of observed mutations and the fact that the se-
lected phenotype depends on mutations at specific
sites of the fusion gene (as opposed to loss-of-function
mutations in the EGFP), the type and the sequence
context of the mutations observed are not indicative of
the AID/APOBEC1 mutational preferences. This is in
line with previous studies in which A/T mutations rep-
resented 33 to 50% of all unique BCR-ABL1 mutations
induced by AID [41,42].
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Figure 3 APOBEC1 induces a mutator phenotype in a human
chronic myeloid leukemia cell line. Frequency of imatinib-resistant
clones arising from 107 K562 cells expressing either mammalian APO-
BEC1s, AID, or a control plasmid seeded in the presence of 1 μM imatinib
(control/APOBEC1, P < 0.05). Imatinib resistance was confirmed by
growing the clones in imatinib-supplemented medium.
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Figure 2 Human APOBEC1 induces a mutator phenotype in bacteria. (A) Frequency of rifampicin-resistant clones in cultures of Escherichia
coli transformed with APOBEC1 expression constructs (rat or human) or empty vector. Each point represents the mutation frequency of an
independent overnight culture. The median mutation frequency is indicated. (B) Distribution of independent rpoB point mutations identified in
rifampicin-resistant clones from bacteria transformed with human APOBEC1 (black changes above the sequence), rat APOBEC1 (black changes
below the sequence), or empty plasmid (brown changes below the sequence). The number of independent colonies is indicated in parentheses.
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Thus, our findings show that APOBEC1 can induce som-
atic mutations in vertebrate cells. Such an APOBEC1-
induced mutator phenotype could play a role in the onset
of cancer previously observed in mice. On the other hand,
there is no evidence so far linking APOBEC1 to any human
cancer.
We therefore searched the Gene Expression Omnibus
(GEO) repository [43] for specific types of cancer in
which APOBEC1 was overexpressed. We found that, in
striking contrast to normal esophageal mucosa, the ex-
pression levels of APOBEC1 in esophageal adenocarcin-
omas (EACs) are comparable to those observed in the
small intestine, where APOBEC1 is expressed at its high-
est levels [44-46] (Figure 4A; Additional file 3). Indeed,
in individual matched pairs of normal esophageal mu-
cosa and EAC, APOBEC1 is consistently overexpressed
in EACs (Figure S3B in Additional file 3). In comparison,
other AID/APOBECs such as AID and APOBEC2 are
not expressed. An increased expression of APOBEC3s in
EACs cannot be excluded: in the dataset from Kim et al.
[44] there is a statistically significant increase of APO-
BEC3A (Additional file 3), which is lost when comparing
normal/EAC pairs (data not shown); on the other hand,
in the dataset from Kimchi et al. [45], it is APOBEC3B
that is increased in EACs, albeit not at the levels of
APOBEC1 (data not shown).
The assessment of the expression levels of the APO-
BEC3s in the datasets from Kimchi et al. [45] and
Stairs et al. [46] is confused by the U133A Affymetrics
platform used (due to cross-hybridizing probes, as dis-
cussed in Burns et al. [30]). On the other hand, the
data from Kim et al. [44] could be informative of the
expression levels of several APOBEC3s (see discussion
in Additional file 4).Interestingly, a marked increase of APOBEC1 is also
found in Barrett’s esophagus, a condition closely related
to adenocarcinomas, both epidemiologically and genetic-
ally, as the same hallmark DNA/genomic alterations are
seen in both [49-52]. In contrast, this is not the case for
the other AID/APOBECs (Figure S3A in Additional file
Table 1 List of the non-clonal mutations identified in the BCR-ABL1 fusion gene from imatinib-resistant K562 clones
Samples Position AA change Codon change Sequence context
1,503 E495G GAA > GGA
Control 1,472 R491Q CGG > CAG GCCGG
1,503 Silent TTT > TTC
633 G100C GGC > TGC GCCTA
AID 395 Silent AAA > AAG
568 G190D GGC > GAC TGCCA
633 T212A ACG >GCG
987 G155D GGC > GAC GGCCA
607 L203M CTG > ATG CCCTG
Rat APOBEC1 613 E205K GAG > AAG CTCGG
764 K255T AAG > ACG
987 Silent GGG > GGT TTCCC
1,245 silent AGC > AGT AGCCG
758 R253H CGC > CAC TGCGC
841* silent CTG > TTG AGCTG
697 H233D CAT >GAT TTCAT
Human APOBEC1 699 H233D CAT > GAC
1,149* Silent GCC > GCA GCCAT
1,245* F415L TTT > TTG
The region analyzed (encompassing exon 13 of BCR and exon 9 of ABL1) includes the imatinib-binding region of the fusion gene. The asterisk indicates mutations
found in the same clone. The local sequence context for the mutations at cytosines is shown. Compared to the AID-induced mutations found in previous reports
(mutations in approximately 30% of the sequences) [41,42], we found approximately one mutation in each of the clones analyzed. This is explained by the differ-
ent procedures we used to select resistant clones: whereas the other studies focused on competing bulk populations of AID-transfected GFP(+) cells and control
GFP(−) cells, we analyzed individual clones arising from the same number of cells plated in the presence of imatinib.
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metaplasia that is characteristic of Barrett’s esophagus,
whereby the normal esophageal epithelium is replaced
by cells with intestinal features.
AID/APOBEC mutational signature in esophageal
adenocarcinomas
In human tumors derived from mature B cells there are
characteristic chromosomal translocations and other muta-
tions that can be regarded as a veritable AID mutational
signature [28,53]. Other AID/APOBECs have been shown
to induce DNA damage and somatic mutations [30,54,55],
and they are involved in kataegis, clusters of mutations
observed in some cancer genomes [29,32,35,56,57]. An
AID/APOBEC mutational signature can be observed in
genes highly mutated in cancer [39] and in cancer genomes
and exomes [31,33-35,58]. Based on this, we have looked at
the data from a recent study on EACs [47] in which at least
two mutational signatures had been observed: A to C trans-
versions in the context of the ApA dinucleotide, and C to T
transitions at CpG sites. Our re-analysis shows that muta-
tions at non-CpG sites represent about 55% of all muta-
tions at Cs, and the sequence context observed in these
non-CpG mutations is similar to that ascribed to AID/APOBEC action (Figure 4B). Such sequence context also
resembles that observed for APOBEC1 [15,16,39] as
well that we found in APOBEC1-expressing DT40 cells
(Figure 1D).
The mutational sequence context at position −1 in
EACs is closer to that observed in tumor types in which
APOBEC3B is expressed alongside other AID/APOBECs,
including APOBEC1 [31]. Moreover, an analysis of the
dinucleotides 5’ to a mutated C shows that the ratio bet-
ween pyrimidine and purine residues at position −2 varies
among the tumor types in which an AID/APOBEC muta-
tional signature is present [30,31,33-35,58]. Indeed, the
pyrimidine/purine ratio in EACs is the lowest among the
different tumors, with the tumors with high expression of
APOBEC3B displaying the highest ratio (Additional file 5).
There is no direct evidence of correlation between
mutation signature and APOBEC1 expression because of
the lack of expression data in Dulak et al. [47]. However,
different studies show variable levels of APOBEC1 over-
expression in EACs (Figure 4; Figure S3A-C in Additional
file 3), providing indirect evidence of such correlation. It is
noteworthy that APOBEC1 is markedly overexpressed in
all samples from Barrett’s esophagus (Figure 4; Figure S3A,
C,D in Additional file 3).
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Figure 4 Upregulation of APOBEC1 and mutational context in
esophageal adenocarcinomas. (A) Expression levels of APOBEC1 in
a cohort of samples from normal esophagus, Barrett’s esophagus
and EACs. The data were extracted from a recent study analyzing
the transcriptome of EAC using microarrays [44], normalized on
TATA-binding protein (TBP) expression levels and shown as
median-centered Log2 values. Differences between the various
sets of data are statistically significant (P < 10−4 by one-way
ANOVA coupled with Tukey’s test). Details of APOBEC1 expression
patterns from this and other studies are shown in Additional file 3.
(B) Sequence context for the mutated cytosine residues in EAC exomes
from a recent study [47]. The trinucleotide sequence context is shown
for mutations at Cs (All C), at CpG and at non-CpG sites as a weblogo
[48]. The expected sequence context for random mutations at cytosines
in the human exomes is shown (P < 0.0001 for the first position at
non-CpG sites by Chi-square analysis).
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Barrett’s esophagus reports that 71% of all mutations are
targeted to C/G base pairs, with a strong bias towards
transition mutations (Ts/Tv ratio at CpH sites of 1.69)
[52]. Such a trend is present also in EACs associatedwith Barrett’s esophagus compared with those that are
not associated (Additional file 6; Ts/Tv of 1.22 versus
1.01). If we consider the marked overexpression of APO-
BEC1 in Barrett’s esophagus, it is suggestive that the
AID/APOBEC mutational signature is more evident
(albeit not significantly different) in EACs associated
with Barrett’s esophagus compared with those that are
not (Additional file 7).Conclusions
DNA deaminases perform various functions within an
organism. Unlike the APOBEC3 genes, which physio-
logically exhibit a broad expression pattern [59], the
expression of AID and of APOBEC1 is limited to few
tissues in which they exert their physiologic activity.
Ectopic expression of AID (especially outside the
B-cell lineage) results in mutations and cancer forma-
tion [60,61]. This suggests that tissues and cells that
require these deaminases in the nucleus and hence
near their own genome have developed protective
regulatory mechanisms. This is seen in mature B cells,
where AID expression is regulated at the transcriptional
level as well as in terms of protein stability and localization.
On the other hand, cells that do not physiologically express
these deaminases could lack this layer of protection and be
more susceptible to self-induced DNA damage (for ex-
ample, [60,62]).
By analogy, we can presume that cells physiologically
expressing APOBEC1 have devices to protect them from
its aberrant activity, whereas those not normally expressing
APOBEC1, such as the esophageal epithelium, may have no
such protection. We have shown here that APOBEC1 can
induce mutations in genomic DNA. Together with previous
findings linking APOBEC1 presence/absence with the in-
duction of tumors in mice [26,27], our experimental results
and our observations in EACs indicate that APOBEC1
could be involved in the onset of cancer by targeting gen-
omic DNA directly.
We do not know yet at which stage in EAC oncogen-
esis AID/APOBECs exert their mutagenic potential;
however, since Barrett’s esophagus can be regarded as a
precursor of EAC, and since genomic alterations of EAC
are already seen in Barrett’s esophagus [49-52], we sur-
mise that AID/APOBECs play a role at an early stage,
even though further studies will be needed to assess the
specific contribution of APOBEC1 compared with other
AID/APOBECs. In addition, we must consider that,
through RNA targeting, APOBEC1 can alter a number
of cellular functions [11,13,14,27]. It is possible, there-
fore, that these changes, associated with APOBEC1
mutagenic activity, may also be boosting its oncogenic
potential and drive both the onset and the progression
of cancer.
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Plasmids and mutator assay in bacteria
The EGFP-expressing construct used for the DT40 experi-
ments was built by subcloning on a pBluescript SK +
backbone the beta-actin promoter (XhoI/NheI), the
EGFP coding sequence (NheI/KpnI) and a Blasticidin-S
resistance cassette (BamHI). Rat and human APOBEC1
were PCR-amplified (rat forward primer AAAGCTAG
CATGAGTTCCGAGACAGGCCCTGTA, rat reverse
primer AAATGTACAAGATCTCATTTCAACCCTGT
GGC; human forward primer AAAGCTAGCATGACT
TCTGAGAAAGGTCCT, human reverse primer AA
ATGTACAAGATCTCATCTCCAAGCCACAGAAGG)
and cloned into the pAIDexpressPuro2 expression vec-
tor [63] under the control of the beta-actin promoter.
Depending on the restriction enzymes used for cloning, the
final constructs encoded either APOBEC1 or APOBEC1-
IRES-EGFP (NheI-BsrGI or NheI-BglII). The construction
of the AID-IRES-EGFP expression construct is detailed in
[64]. An empty plasmid with a puromycin cassette [65] was
used as control for the DT40 experiments. An analogous
one expressing EGFP was used in the experiments on K562
cells. The rat APOBEC1 vector for bacterial expression was
described in Harris et al. [15]. The human APOBEC1 cod-
ing sequence was cloned into pTrc99a (forward primer,
TTTCCATGGCCATGACTTCTGAGAAAGGTCC; re-
verse primer, AAATGTACAAGATCTCATCTCCAAG
CCACAGAAGG; NcoI/BglII). The rifampicin-resistance
reversion assay used to test the induction of a mutator
phenotype was performed as described in Petersen-Mahrt
et al. [66] and Harris et al. [15], but with induction of the
AID/APOBEC at 18°C for 24 hours in order to increase the
viability of the bacteria and to obtain better resolution
(Additional file 8).
Cells, transfections, and protein expression
sIgM+ ψV− AID−/− DT40 cells [38] were maintained in
RPMI1640 9% fetal bovine serum (FBS), 1% chicken
serum (Life Technologies, Carlsbad, CA, USA), 50 μM
2-mercaptoethanol at 37°C in 5% CO2, and transfected
as previously described [63]. Cells were selected with
25 μg/ml blasticidin or 0.25 μg/ml puromycin, depend-
ing on the plasmid used. DT40GFP cells were prepared
by selecting independent clones stably transfected with
the EGFP construct. Southern blot analysis using an
EGFP fragment as probe were performed to select for
DT40GFP clones bearing a single EGFP copy.
K562 cells were maintained in DMEM supplemented
with 10% FBS at 37°C in 5% CO2; 10
6 cells and 5 μg of
plasmid were used to electroporate K562 cells (250 V,
950 μF, Biorad GenePulserII Hercules, CA, USA). K562
cells were selected with 3 μg/ml puromycin.
EGFP fluorescence was assayed by flow cytometry on
a BD Accuri C6 cytometer (Franklin Lakes, NJ, USA).Expression of APOBEC1 and AID was monitored by
western blot. Cells were lysed (RIPA) and - after SDS-
PAGE - the proteins were detected using either a primary
goat anti-APOBEC1 antibody (1:5,000; Santa Cruz
Biotechnology (Dallas, TX, USA), a monoclonal anti-
AID antibody (hAnp52-1, 1:8,000) [64], or a beta-actin
antibody (1:10,000; Sigma (St. Louis, MO, USA).
Assaying APOBEC1 activity in DT40 cells
After electroporation with the APOBEC1/control con-
structs, DT40GFP cells were plated in 96-well plates for
selection. Independent DT40GFP clones were used. Single
clones were picked after approximately 8 days and ex-
panded. We then analyzed 105 cells by flow cytometry to
assay the loss of EGFP fluorescence at 14 and 28 days after
transfection. All experiments were repeated at least three
times. For the mutation analysis, the GFP(−) population
from independent clones was sorted using a BD FACSAria
(Franklin Lakes, NJ, USA). After expansion the genomic
DNA of the sorted population was prepared and the EGFP
coding sequence was amplified by touch-down PCR using
the KOD polymerase (CGTAAACGGCCACAAGTTCAG,
ACTGGGTGCTCAGGTAGTGGT, 10 touchdown cycles
plus 20 amplification cycles). The PCR fragments
were cloned in pCR-Blunt II-TOPO according to the
manufacturer’s instructions (Life Technologies, Carlsbad,
CA, USA), and independent bacterial clones were se-
quenced (Additional file 9).
Assaying APOBEC1 activity in K562 cells
Our failure to amplify by RT-PCR the catalytically active
AID/APOBECs in K562 cells in the presence/absence of
imatinib suggests that they are not expressed. This is in
line with available data in GEO datasets GSE26821 and
GSE51083. We have produced independent clones of K562
cells stably expressing APOBEC1-IRES-EGFP, AID-IRES-
EGFP, or the control vector. We seeded 107 cells from these
clones in 96-well plates in medium supplemented with
1 μM of imatinib. Imatinib-resistant colonies grew after ap-
proximately 3 weeks, and were picked for expansion. After
confirming the ability of these clones to grow in the pres-
ence of imatinib, total RNA was prepared and the muta-
tions in the region encompassing exon 13 of BCR and exon
9 of ABL1 were analyzed as described in [42]. The number
of independent imatinib-resistant clones that were analyzed
is: rat APOBEC1, 8; human APOBEC1, 5; AID, 6; control,
6. There are between 5 and 11 copies of the BCR-ABL1 fu-
sion gene in K562, with many of these copies inactivated by
indels. In our sequencing we found evidence for at least five
variants of the PCR-amplified BCR-ABL1 fragment, only
one of which could translate a proper BCR-ABL1 fusion
protein. Typically - after cloning in a plasmid - we se-
quenced between 12 and 24 bacterial colonies for each
imatinib-resistant clone in order to discriminate the active
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mutational status (Additional files 10 and 11).
Expression of APOBEC1 in the esophagus and mutational
analysis
Expression data were downloaded from GEO [43]. The
data from Kimchi et al. [45], Kim et al. [44], and Stairs
et al. [46] correspond to GEO dataset accession num-
bers GSE1420, GSE13898 and GSE13083, respectively.
All data were normalized on TATA-binding protein ex-
pression levels and their value centered on the median
of the samples as Log2 values. Details of the statistics
used are provided in the figure legends.
Sequence context analysis
The sequence context of the mutations at cytosines in
EACs was calculated using the mutation data from the
exome analysis reported in Dulak et al. [47]. Only single-
nucleotide changes were considered for analysis. Duplicate
mutations were used only if originating from different
tumor samples. For the analysis, we used the mutations at
cytosines on both strands. Based on the genomic coordi-
nates of the mutations, the local sequence context was ex-
tracted using a Perl script (Additional file 12). The expected
mutational context was calculated based on the exonic se-
quences of the reference genome used for the exomes
(build GRCh37). The trinucleotide representing the local
context of mutations at C either from the DT40 experi-
ments, from the EAC data, or from the control exome were
then fed into the weblogo interface [48].
Additional files
Additional file 1: Figure S1. Expression of the transduced proteins in
stably transfected cells. (A) Western blot analysis of representative DT40
clones stably expressing APOBEC1. (B,C) Western blot analysis of
representative K562 clones stably expressing rat APOBEC1, human
APOBEC1, or AID as indicated. The blots were stripped and
rehybridized with beta-actin antibody as control for loading.
Additional file 2: Figure S2. Mutational sequence context in DT40
cells. Local sequence context for all residues present on both strands of
the analyzed EGFP fragments (expected), for the mutated residues in the
APOBEC1-expressing clones (APOBEC1) and in the controls (Control).
Additional file 3: Figure S3. Expression levels of APOBEC1 in esophageal
tissues. All data were normalized on TATA-binding protein (TBP) expression
levels and shown as median-centered Log2 values. (A) Expression levels of
the AID/APOBECs in the study by Kim et al. [44], comparing normal esophagus
samples to esophageal adenocarcinoma (EAC) and Barrett’s esophagus
samples. Each circle represents either a normal (blue), tumor (red),
or Barrett’s (green) sample. The median is indicated as a black bar. Only
differences in the expression levels of APOBEC1 (Normal/Tumor/Barrett’s
samples) and APOBEC3A (Normal/Tumor samples) reach statistical significance
(P < 0.0001 by one-way ANOVA coupled with Tukey’s test). (B) Levels
of APOBEC1 in samples from matched normal/EAC pairs [44]. While an
increased expression was present also with regards to APOBEC3A, only
in the case of APOBEC1 did the differences reached statistical significance
(P= 0.0002 by Wilcoxon signed rank test). (C) Levels of APOBEC1 in matched
samples from normal esophagus, EACs, and Barrett’s esophagus in [45]
(P = 0.0155 by repeated measures ANOVA coupled with Tukey’s test,with differences between tumors and Barrett’s samples not statistically
significant). (D) Comparison of APOBEC1 expression levels in matched
samples from normal/Barrett’s esophagus pairs and in small intestine
[46] (P = 0.015 by Wilcoxon signed rank test).
Additional file 4: Table S1. Possible cross-hybridization of the APOBEC3
probes in the Illumina GPL6102 chip. The data from Kim et al. [44] originate
from the Illumina GPL6102 beadchip. This platform uses 50-mer probes that
allow for a more specific analysis compared with the Affymetrix ones: some
probes (A3A, A3C, A3D, A3F) could still cross-hybridize with other genes (albeit
with non-transcribed/intronic portions of other APOBEC3s), and others (A3B,
A3G, A3H) should not. The cross-hybridization potential of the individual
probes (matching bases/length of the probe) is shown. The location of the
probe on the gene if outside of the coding region is shown in parentheses
(intron, in; untranscribed region in the 3’ of the gene, downstream).
Additional file 5: Table S2. Mutational sequence context at position −2 in
tumors expressing AID/APOBEC genes. The table shows the pyrimidine/purine
ratio at position −2 in cancers for which the AID/APOBEC mutational signature
has been associated with AID/APOBEC expression [30,31,33,58]. The expression
of the various AID/APOBECs has been taken from Lin et al. [58] for the ESCC,
and from Burns et al. [30,31] and Roberts et al. [33] for the other tumor types.
The expression in EACs has been extrapolated from Kim et al. [44]. An asterisk
indicates whenever the expression has been established through
microarray analysis (as opposed to real-time PCR). The parentheses
indicate the possible cross-reactivity of a microarray probe with other
AID/APOBECs (Additional file 4).
Additional file 6: Figure S4. Transition/transversion ratio in mutations
at CpH sites in EAC associated or not with Barrett’s esophagus [47]. The
number of tumors and the average in each subset are indicated in the
legend and beside the box, respectively (P = 0.0192 by two-tailed t-test
with Welch’s correction). The extra points represent the values external to
the 5th to 95th percentile interval.
Additional file 7: Figure S5. Sequence context for the mutated
cytosine residues in EAC associated or not with Barrett’s esophagus [47].
The trinucleotide sequence context is shown for both CpG and non-CpG
mutations as a weblogo [48].
Additional file 8: File containing the chromatograms of the
sequences obtained from the Rifampicin assay.
Additional file 9: File containing the chromatograms of the
sequences obtained from the DT40 experiments.
Additional file 10: File containing the chromatograms of the
sequences obtained from the K562 experiments.
Additional file 11: File containing the chromatograms of the
sequences obtained from the K562 experiments.
Additional file 12: File containing the Perl scripts used in the
mutation analysis.
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